Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP334272.RAcnQlnwrtyqDbns5L69SqToqp76nXfA6F8sDzsQIYbP4130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP334272.RAcnQlnwrtyqDbns5L69SqToqp76nXfA6F8sDzsQIYbP4130_assertion type Assertion NP334272.RAcnQlnwrtyqDbns5L69SqToqp76nXfA6F8sDzsQIYbP4130_head.
- NP334272.RAcnQlnwrtyqDbns5L69SqToqp76nXfA6F8sDzsQIYbP4130_assertion description "[CD20 is a crucial target to B-non-Hodgkin lymphoma (NHL), in fact, a humanized anti-CD20 monoclonal antibody, rituximab, is widely applied in clinical practice.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP334272.RAcnQlnwrtyqDbns5L69SqToqp76nXfA6F8sDzsQIYbP4130_provenance.
- NP334272.RAcnQlnwrtyqDbns5L69SqToqp76nXfA6F8sDzsQIYbP4130_assertion evidence source_evidence_literature NP334272.RAcnQlnwrtyqDbns5L69SqToqp76nXfA6F8sDzsQIYbP4130_provenance.
- NP334272.RAcnQlnwrtyqDbns5L69SqToqp76nXfA6F8sDzsQIYbP4130_assertion SIO_000772 23142221 NP334272.RAcnQlnwrtyqDbns5L69SqToqp76nXfA6F8sDzsQIYbP4130_provenance.
- NP334272.RAcnQlnwrtyqDbns5L69SqToqp76nXfA6F8sDzsQIYbP4130_assertion wasDerivedFrom befree-20140225 NP334272.RAcnQlnwrtyqDbns5L69SqToqp76nXfA6F8sDzsQIYbP4130_provenance.
- NP334272.RAcnQlnwrtyqDbns5L69SqToqp76nXfA6F8sDzsQIYbP4130_assertion wasGeneratedBy ECO_0000203 NP334272.RAcnQlnwrtyqDbns5L69SqToqp76nXfA6F8sDzsQIYbP4130_provenance.